Shannon C. Trotter, DO, FAOCD, a certified dermatologist at Dermatologists of the Central States in Ohio, discusses immunotherapy options for the treatment of advanced cutaneous squamous cell carcinoma (cSCC) and why dermatologists should remain involved in the care process even after patients are referred to oncology. In an interview with HCPLive, Trotter highlights the importance of dermatologists’ active role in the care process, noting that the care of patients with locally advanced or metastatic cSCC should continue even after they are referred to oncology. In the interview, Trotter discusses immunotherapy options for advanced cSCC, as well as the expected Medicare cuts and the future of artificial intelligence in skin cancer care.[^1] Trotter noted that approximately 95% of cSCC cases are treatable, but that roughly 5% become more challenging to manage. She highlighted three approved immune checkpoint inhibitors for locally advanced or metastatic cSCC: pembrolizumab (Keytruda), cemiplimab (Libtayo), and cosibelimab (Unloxcyt). In particular, research on formulations to be injected with cemiplimab could play a role for dermatologists in the clinic setting. “They may seem far away from dermatologists, but in fact, we are the quarterback in skin cancer. We may be the first to detect it, whether it’s on the skin or by feeling a lymph node. So even if our patients are referred to oncology, we need to remain involved in the care process,” said Trotter.
Trotter also evaluated the anticipated Medicare cuts in terms of patient access. Older adults who are more affected by squamous cell carcinoma may experience delays in diagnosis and treatment. With early detection, the survival rate for melanoma is approximately 100%; Trotter added that the dermatology community has signed a petition against the cuts. Looking ahead, Trotter highlighted augmented intelligence, which combines artificial intelligence with physician reasoning, as a significant opportunity in both melanoma and non-melanoma squamous cell carcinoma. New diagnostic tools may enable earlier detection. Genomic profiling can provide prognostic information, either alone or in combination with artificial intelligence, and may guide treatment decisions in the future. [^1]: Schlesinger TE, Trotter SC. Seminar-in-depth: deep dive on cutaneous squamous cell carcinoma and the latest in immunotherapy. Presentation: 2026 Fall Clinical Dermatology Conference; October 8-11, 2026; Las Vegas, NV.
Bu gelişme hakkında düşüncelerinizi, donanım deneyimlerinizi veya sorularınızı Community Forumumuzda paylaşın.
读者社区
0 条评价
您可以分享您的经历；有关诊断、治疗或紧急情况，请咨询专业医护人员，而非参考评论。